title: Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
abstract: Physostigmine is a cholinesterase inhibitor which enhances central and peripheral cholinergic activity. In this study, we explored in persons with Alzheimer's disease (AD) the effects of an acute dose of physostigmine in patients receiving chronic physostigmine treatment on the activity of the cholinergically regulated noradrenergic and arginine vasopressin (AVP) systems. Specifically, we estimated the effects of sustained release oral physostigmine on central and peripheral noradrenergic and AVP systems by measuring norepinephrine (NE) and AVP in cerebrospinal fluid (CSF) and plasma. Lumbar punctures were performed in both physostigmine and no drug treatment conditions. In some subjects the effects of physostigmine on the plasma AVP response to the osmolar stimulus of a hypertonic saline infusion also were measured. NE concentrations in both CSF and plasma were significantly lower in the physostigmine than in the no drug condition. AVP concentrations did not differ between conditions in either compartment, nor did physostigmine affect the AVP response to hypertonic saline. Physostigmine appears to decrease both central and peripheral noradrenergic activity in AD.
authors.affiliation: Geriatric Research, Education, and Clinical Center, Seattle, WA, USA.
authors.forename: E R
authors.initials: ER
authors.lastname: Peskind
authors.forename: D
authors.initials: D
authors.lastname: Wingerson
authors.forename: M
authors.initials: M
authors.lastname: Pascualy
authors.forename: L
authors.initials: L
authors.lastname: Thal
authors.forename: R C
authors.initials: RC
authors.lastname: Veith
authors.forename: D M
authors.initials: DM
authors.lastname: Dorsa
authors.forename: S
authors.initials: S
authors.lastname: Bodenheimer
authors.forename: M A
authors.initials: MA
authors.lastname: Raskind
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D001127:Arginine Vasopressin / Q000134:cerebrospinal fluid*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000134:cerebrospinal fluid*; D010830:Physostigmine / Q000008:administration & dosage* / Q000009:adverse effects; D014882:Water-Electrolyte Balance / Q000187:drug effects
chemical_list: D002800:Cholinesterase Inhibitors; D003692:Delayed-Action Preparations; D001127:Arginine Vasopressin; D010830:Physostigmine; D009638:Norepinephrine